Key findings:

The percentage of opioids testing positive for benzodiazepines in the region (41%, 19 of 46 samples) increased from last month, but trends may be hard to infer due to the small number of samples over a large region. Etizolam, the predominant benzodiazepine in expected opioids, may be missed by drug checking technologies. This means that the true rate may be higher than reported here.

Fentanyl was detected in 3 stimulant samples. While these results are concerning, two of the findings can be explained by cross-contamination after purchase.

Read the full report.